This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Researchers at the Indian Institute of Science (IISc) have found that picolinic acid, a natural compound produced by mammalian cells, can block several disease-causing viruses such as SARS-CoV-2 and influenza A viruses. The Institute is now looking for partners in pharmacompanies to pursue further clinical development of the findings.
Indian healthcare providers and pharmacompanies pace up their efforts with early detection and research for new medicines to combat the spread of tuberculosis as drug resistance concerns emerge. TB is a significant public health threat, with an estimated 10 million annual cases. India shares the highest TB burden with 2.69
As part of our patient advocacy efforts, at FindMeCure we are dedicated to creating a bridge between patients and the world of clinicalresearch. This includes spreading clinical trial awareness, connecting patients to the trials they are interested in but also speaking up about the issues in the clinicalresearch industry. .
Data is readily shared and leveraged for decision-makers to gain insight that can help clinicalresearch. Jessica Hagen is a freelance life sciences and health writer and project manager who has worked with VR health companies, fiction/nonfiction authors, nonprofit and for-profit organisations, and government entities.
The Department of Pharmaceuticals (DoP) has issued a new Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, permitting pharmacompanies to provide brand reminders such as informational and education items and free samples to medical professionals with restrictions on sample packs and total value.
The pharmacompanies’ thrust on R&D to develop better medicines and the demand in hospitals for advanced medical technologies driven by artificial intelligence, remote patient monitoring and wearables are transforming patient care.
Indian pharma sees immense value in US FDA’s insistence for aluminum content and labelling recommendations for the Small Volume Parenterals Drug Products and Pharmacy Bulk Packages. Pharmacompanies in the country have increasingly made a shift to nutritional based prescription and over the counter products.
The Delhi High Court has granted ten days’ time to the Government of India and the nation’s drug regulator to file a counter affidavit on the petitions filed by almost 28 pharmacompanies against the order prohibiting manufacturing, distribution and sale of 14 FDCs licensed prior to the year 1988, in the beginning of June. […]
This is partly due to the differing business models used by pharmacompanies and digital therapeutic developers. To do that, the company would need to do clinicalresearch that features both therapies, he adds. Securing reimbursement for digital therapeutics also continues to impede its uptake.
The competition highlights companies that demonstrated innovative solutions, technologies, and services that have the potential to make the greatest impact for biotech and pharmacompanies. The company was selected for its industry leading Virtual Care Management (VCM) program.
EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharmacompanies. But the EU draft document says that the changes will make medicines more affordable, improve unequal access to medicines across the EU, and fulfil unmet patient needs.
In the UK, research organisations and pharmacompanies are working to find ways to reach this goal, using data to inform commercial clinicalresearch now, and how this foundation can be built upon in the future. The current data landscape in commercial clinicalresearch.
That was the message from ‘The New Normal: Balancing the rapid evolution of trial design with patient need’ panel at the NIHR’s ClinicalResearch Network Virtual Event on Delivering Complex and Innovative Design (CID) Studies. Thankfully, many pharmacompanies seem to be gradually improving on this. Listening to patients.
Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharmacompanies can help make patient involvement in HTA more impactful. The earlier HTAs, researchers and pharmacompanies can start that engagement the better.
It’s been developed in collaboration with pharmacompanies to offer a way to incorporate EEG testing in clinical trials much more easily than at present, with the opportunity to harvest much more data over time.
Across the industry, pharmacompanies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?
A group representing pharmacompanies selling precision therapies for cancer has called for a change to the way genomic testing is done in Scotland, to make sure patients get access to targeted drugs.
The arrival of COVID-19 meant that certain virtual technologies became essential for clinical trials to continue, bringing certain activities into the patient’s home and allowing for further activities to be conducted remotely. The post Decentralised trials: beyond the pandemic appeared first on.
. “The cost of developing a new drug is extortionately high,” said Landray, adding that a very large proportion of those costs is in phase 3, and that means many promising therapies may never be taken forward by pharmacompanies.
The annual peer-reviewed awards program from the publisher of Fierce Biotech and Fierce Pharma highlights companies that have demonstrated innovative solutions, technologies, and services and have the potential to make the greatest impact for biotech and pharmacompanies.?. 2020 Accolades. 2018 & 2019 Achievements.
Individuals looking to start, or further their careers in clinicalresearch can benefit from the inside look that experts from Syneos will provide in the webinar. This will help job seekers learn more about specific positions and the industry as a whole.
Ben Hargreaves discovers why medical research in the area has shifted from being highly controversial to being backed by major pharmacompanies and venture capital. The image of psychedelic drugs within medical research is changing. A psychedelic renaissance.
This philosophy was behind Xperiome’s recent decision to split into two different functions – Raremark, a community where patients and carers can share their experiences of living with rare diseases, and Xperiome, which leverages those insights for pharmacompanies looking to develop drugs for these conditions.
Collaboration in clinicalresearch. The last 18 months have seen some incredible scientific leaps directly tackling the pandemic, brought about by unprecedented alliances seen between pharmacompanies and between academia and pharma. As we look to the future, collaboration is key on many levels.
Even reaching the clinical trial phase offers no guarantees, as only 12% of such drugs receive U.S. Pharmacompanies need tools like AI that can reliably improve this percentage without jeopardizing safety. Learn more about the benefits and challenges of AI and clinical trials, as well as examples of AI’s use in this industry.
Time is also of the essence in drug development, as competitive product-to-market lead times help pharmacompanies improve profitability. Time spent on clinical trials involves investment and being able to predict ADRs assists with improving the success rate. Navro Technology Solutions – AI-Based Pharmacovigilance.
Verily is also looking to accelerate a number of its key businesses, with the company calling out clinicalresearch ecosystem Baseline, COVID-19 testing platform Healthy at Work and virtual clinic Onduo. Meanwhile, the last 12 months have seen a refocusing at Onduo.
Beyond digital clinical measures, digital solutions are maturing to address major challenges facing clinicalresearch and offer enormous promise to support the key performance indicators (KPIs) for every member of our industry. Pharmacompanies with more mature digital strategies are able to focus on questions of scale.
. “We are already making an impact for our customers and for medical research, by raising patient trust and engagement in their care,” he continued, pointing to ongoing relationships with a wide range of study partners, including clinicalresearch organisations, pharmacompanies, and academic medical centres.
Dr Jay Mei from Antengene tells us how the Asia Pacific region is opening up to innovative pharmacompanies, and gives tips for companies navigating this enormous market. Dr Jay Mei has nearly 30 years of experience in clinicalresearch and development of oncology therapeutics globally. About the interviewee.
The ‘PEP Talks’ monthly e-newsletter has approaching 50 pharmacompanies as subscribers and the inaugural ‘Patient Engagement Day’ on September 01 st achieved an inspirational number of downloads of toolkits for ways to ‘Amplify the Patient Voice’ as the launch theme.
They include mistrust of the clinicalresearch system, unfeasible trial design, and time and resource constraints. An increase in pharma organisations seeking patient input, however, is bound to place additional pressure on already-stretched patient advocacy groups, said Ellen Coleman, president and CEO of VOZ Advisors. “Is
While randomised clinical trials remain the gold standard for testing medicines, showing how they perform in real-world settings is gaining increasing importance for both regulators and payers. Eversana push into RWD gathered momentum last year when it launched a data management and analysis platform for chronic diseases.
Data-Driven Personalization : Using real-time insights, pharmacompanies can deliver tailored content to physicians and patients. However, pharma marketers must navigate strict compliance regulations to avoid misleading advertising or privacy violations. How do pharma brands ensure compliance in digital advertising?
Data-Driven Personalization : Using real-time insights, pharmacompanies can deliver tailored content to physicians and patients. However, pharma marketers must navigate strict compliance regulations to avoid misleading advertising or privacy violations. How do pharma brands ensure compliance in digital advertising?
Pharmacompanies have begun to explore a host of novel digital endpoints that could have far-reaching implications for accelerating drug development and adoption. That is what’s exciting – as we see DCTs continue to play such a key role that they become the standard for the future of clinicalresearch,” predicts Reites.
As pharmacompanies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely.
Rothenberg did not provide any information as to what his next role may be – whether he will take over the helm of a pharmacompany or assume a role on one or more boards of directors. I have every confidence in her continued success in this new role,” Rothenberg said.
Christopher Boone, global head of health economics and outcomes research at AbbVie, advises: “Evidence generation in drug development is ripe for innovation in the digital era and the expanded use of real-world evidence presents a clear enabler to saving time and money. It is true that RWD contains more potential bias as a result.
Additionally, the work being done within Rare Disease networks, formed of specialty sites, pharmacompanies, CROs, researchers, and other stakeholders, can all benefit from the value generated by real world genomic data, as outlined by panellist Dr Joanne Hackett, Head of Genomic and Precision medicine at IQVIA.
That could include original observations and measurements of clinical study participants, such as lab results, imaging data, and patient medical charts. It has been quick to give reassurance that any analysis of patient data will comply with the EU’s data protection requirements.
The clinical trial landscape overall has evolved significantly with key changes in the social, ethical and regulatory environment globally with the creation of guidance by regulators with new regulatory pathways for approval of products specifically developed for diseases in LMIC and public health emergencies.
With a competitive landscape and ever-evolving regulations, having effective pharmaceutical marketing strategies is crucial for pharmacompanies looking to stand out. Educational Content Is King Healthcare professionals value well-researched, credible information.
Clinical data management is important because the data that is collected needs to be accurate, complete and properly analyzed in a timely manner. The advantages of good clinical data management software systems include: Fast data access: Using an advanced clinical data management platform helps pharmacompanies be more efficient.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
189 
Let's personalize your content